ApeX Omni separates funding from trading balances and supports cross collateral. API signing controls and withdrawal liquidity conditions deserve separate checks from a trading-fee headline.
Reviewed 2026-10-14Version 1.0.0No live execution tests
What Matters
Separate the balance you hold from the actions you authorize.
Provider-documentation review of ApeX Omni perpetual trading. Not a live execution test, exhaustive product inventory, security audit or individual eligibility assessment.
Scope: Omni perpetuals and their funding/API workflow. Spot, prediction and tokenized-asset products are outside this brief. Documentation is not proof of current account eligibility or successful execution.
DN Evidence Block
Claims, sources and practical consequences.
Provider-reported
Does a funding deposit immediately become trading margin?
The API guide separates the Omni funding account from the Perps account and describes a transfer between them.
Why it matters: Check available trading balance after the transfer; a completed deposit alone does not establish usable margin.
Current executable quotes and all-in holding costs
Independent fill, stop-loss and withdrawal reliability
Live signing permissions and revocation behaviour
Individual eligibility and current regional restrictions
No numerical all-in cost is calculated. A valid comparison needs contemporaneous quotes for matching assets, product modes, notional sizes, directions and holding periods, with entry, holding and exit costs included.
Your research record
Keep the evidence. Keep its limits.
The receipt preserves the provider sources and research gaps at version 1.0.0.
It is not a recommendation, approval, live quote or alert subscription. No account, balance, wallet or country is requested.
Scope
ApeX Omni perpetual trading (review scope)
Collateral scope
The Omni API reference lists USDT alongside several cross-collateral assets, including USDC. Confirm current eligibility and margin valuation for the chosen asset.
Initial documentation brief. Account-specific conditions and evidence limits are preserved in this version.
Review triggers: Changed official product, fee or margin documentation; A substantiated correction; The 14-day editorial review deadline. No automated provider surveillance runs for this brief.
How to use this research
Provider-reported describes the source of a statement, not an independent endorsement. Unknown and not measured identify evidence gaps. A documentation review does not confer an operational-status classification or establish user eligibility.
DN may receive compensation through commercial links elsewhere on the site. This brief contains no trading CTA or payout-based ranking. A documentation review does not establish current operational status or user eligibility.
Educational research only, not investment, legal or tax advice. Leveraged derivatives can cause substantial losses.